



When your child needs a hospital, everything matters.

# IV Fluid Therapy: Maintenance (Euvolemic) Inpatient

Center for  
Clinical Excellence

Verify that patient is appropriate for this pathway

Euvolemic

and  
Not candidate for enteral  
fluids (oral or NG/G/GJ-tube)  
to maintain euvolemia ?

No or  
Unsure

Go to  
"IV Fluid Therapy:  
Bolus (Hypovolemic)"  
Algorithm

Yes

Maintenance IV Fluids

- Maintenance IV Fluid Selection (LR<sup>\$</sup>, NS<sup>\$</sup>, PL<sup>\$\$\$</sup>)
- Calculate maintenance rate
- Determine need for IV Fluid Additives (potassium and dextrose)
- Compatibility Considerations

Monitoring

- Clinical volume status
- Input/Output
- Daily weight
- Scheduled chem7 (at minimum by 48h of IVF)

Electrolyte abnormality?

(hyperchloremic acidosis,  
hypo- or hypernatremia)

and/or

Hypovolemia?

or

Signs of Volume Overload?

Yes

- Verify continued need for IVFs or discontinue
- Reassess Maintenance IV Fluid selection
- Reassess risk factors for increased ADH
- **Individualize management** based on patients condition

No

Reassess Daily

Tolerates oral fluids or NG/G/GJ-tube  
fluids to maintain euvolemia?

Yes

**Off Pathway.**

Continue with enteral fluids.  
Monitor I/Os.

## Calculating IV Fluid Rate

Holliday-Segar "4-2-1" Rule:

- First 1-10 kg = 4 mL/kg/hr
- Next 11-20 kg = 2 mL/kg/hr
- Next > 20 kg = 1 mL/kg/hr
- Add together for maintenance rate
- Calculation example

BSA method:

- $BSA (m^2) \times 1600 \text{ mL}/m^2/\text{day}$   
= Daily requirement

Maximum Rate:

100 mL/hr is an appropriate  
maximum rate in most patients

- By **day 5** of mIVF, start plans for enteral and/or parenteral nutrition support<sup>32</sup>
- By **day 7** of mIVF, should be transitioned to enteral and/or parenteral nutrition

No



**NATIONWIDE  
CHILDREN'S**

*When your child needs a hospital, everything matters.*

# IV Fluid Therapy: Bolus (Hypovolemic) Inpatient

**Center for  
Clinical Excellence**

Verify that patient is appropriate for this pathway

Additional Guidance for Degree  
of Dehydration Assessment

Is an accurate **pre-illness weight** available  
to determine dehydration severity?

Yes

No

## Gold Standard for % Dehydration:

$$\frac{(\text{PreIllnessWt} - \text{CurrentWt})}{(\text{PreIllnessWt})} \times 100 = \% \text{ of fluid deficit}$$

## Clinical Findings to Assess Dehydration Severity

1. Poor overall appearance
2. Capillary refill >2 seconds
3. Abnormal respirations
4. Decreased skin elasticity
5. Absent tears
6. Dry mucous membranes
7. Sunken eyes
8. Abnormal radial pulse
9. Tachycardia
10. Decreased urine output

**Minimal to Moderate  
Dehydration**  
<10% or ≤6 findings

**Severe/Extreme  
Dehydration?**  
>10% or ≥7 findings

- Consider push-pull administration of fluids
- Consider ICU involvement (ACT)

## Bolus Dosing Guidance

Is fluid bolus orally or via NG/  
G/GJ-tube appropriate?

Yes

**Off Pathway.**  
Continue with enteral fluids.  
Monitor I/Os.

Consider NG in patients  
with PO fluid aversion.  
Shared  
decision-making  
with  
patient/family

**Off Pathway.**  
Continue with enteral fluids.  
Monitor I/Os.

**Patients requiring  
multiple boluses should  
be frequently  
reassessed for signs of  
shock or fluid overload.  
Low threshold for PICU  
involvement (ACT).**

Attempt enteral fluids if feasible

Tolerates oral fluids or  
NG/G/GJ-tube fluids to  
maintain euvoemia?

No

Go to

"IV Fluid Therapy: Maintenance  
(Euvoemic)" Algorithm

**IV Fluid Bolus**  
(20 mL/kg) Isotonic fluid  
**Bolus IV Fluid Selection**

Reassess vital signs & clinical  
findings:  
**Moderate or Extreme  
dehydration?**

Yes

**2<sup>nd</sup> IV Fluid Bolus**  
(20 mL/kg) Isotonic fluid

Reassess vital signs & clinical  
findings:  
**Moderate or Extreme  
dehydration?**

Yes

**3<sup>rd</sup> IV Fluid Bolus**  
(20 mL/kg) Isotonic fluid

- Revisit differential diagnosis
- Consider ACT and vasopressor support
- **Individualized management.**
- **Off pathway**

# Pre-Pathway Validation

## Background

This algorithm is meant to apply to patients who require fluid administration either to recover or maintain euvolemia. The algorithm would generally apply to patients who are unable to maintain euvolemia by enteral fluid intake alone, therefore requiring intravenous fluid administration.

### Target Patient Population:

- Euvolemic but NPO
- Dehydration/Hypovolemia

### Diagnostic Criteria for IV Fluid Therapy.

- Patients should undergo clinical assessment for hypovolemia or hypervolemia, inclusion/exclusion criteria, as well as candidacy for enteral fluid supplementation should occur to ensure fluids are required.

### Consider Alternate Therapy When:

- Enteral fluid administration is an option

### Diagnostic Time-Out

- What else could this be?
- Consider utilizing a diagnostic checklist

## Inclusion Criteria

- IV Fluids needed to rehydrate or maintain euvolemia
- Unable to rehydrate or maintain euvolemia by enteral fluid intake alone
- Prolonged NPO
- 

## Exclusion Criteria

- Corrected gestational age  $\leq 28$  days
- Patients requiring intensive care
- Acute kidney injury or chronic kidney disease
- Diabetic ketoacidosis
- Severe electrolyte derangements requiring intravenous fluid as treatment
- Oncological treatment protocol
- Increased intracranial pressure, pyloric stenosis, burns, shock
- Parenteral nutrition dependent
- Organ failure including renal, cardiac, and hepatic failure
- Fluid overloaded state (hypervolemia)
- Patients under fluid-related study

## Diagnostic Timeout

### Red Flags

- **Risk factors for increased ADH & hyponatremia:**
  - Stress, pain, anxiety
  - Vomiting, diarrhea
  - Infection
  - Recent surgery
  - CNS pathology
  - Medications
- Volume/Fluid overload,
- Hyperchloremic metabolic acidosis
- Hyper- or Hyponatremia
- Hyper- or Hypokalemia
- Hyper- or Hypoglycemia
- Acute Kidney Injury

**Assess Degree of Dehydration**

**Go to Maintenance (Euvolemic)  
Algorithm**

**Signs of Hypervolemia  
(NO IVF)**

**Go to Bolus (Hypovolemic)  
Algorithm**

# Assess Degree of Dehydration

Signs and Symptoms	Degree of Dehydration		
	None or Mild <5%	Moderate 5 - <10%	Severe ≥10%
General Condition			
<i>Infants</i>	Thirsty; alert; restless	Lethargic or drowsy	Limp; cold, cyanotic extremities; may be comatose
<i>Children</i>	Thirsty; alert; restless	Alert; postural dizziness	Apprehensive; cold, cyanotic extremities; muscle cramps
Quality of radial pulse	Normal	Thready or weak	Feeble or impalpable
Quality of respiration	Normal	Deep	Deep and rapid
Skin elasticity	Pinch retracts immediately	Pinch retracts slowly	Pinch retracts very slowly (>2 sec)
Eyes	Normal	Sunken	Very sunken
Tears	Present	Absent	Absent
Mucous membranes	Moist	Dry	Very Dry
Urine output (by report of parent)	Normal	Reduced	None passed in many hours

Adapted from Gorelick MH, Shaw KN, Murphy KO. Validity and Reliability of Clinical Signs in the Diagnosis of Dehydration in Children. *Pediatrics*. 1995;99(5):1-6.

**Return to Maintenance (Euvolemic)  
Algorithm**

**Return to Bolus (Hypovolemic)  
Algorithm**

**Signs of Hypervolemia/Fluid Overload**

**Return to Pre-Pathway Validation**

# Bolus Dosing Guidance

- **Need for bolus dosing determined by clinical condition, vital signs, and clinical volume status assessment**
  - Mild hypovolemia: 10-20 mL/kg bolus of isotonic crystalloid (LR, NS, PL)
  - Moderate-severe hypovolemia: 20 mL/kg isotonic crystalloid
  - In patients >50 kg, use 1000 mL and 500 mL boluses (rather than 20 mL/kg or 10 mL/kg, respectively)
  - Consider push-pull administration and ACT activation for severe hypovolemia, hypotension, refractory tachycardia, or as otherwise clinically indicated
  - Patients requiring bolus dosing should be frequently reassessed and PICU involvement (ACT) should be considered
- **Selection of fluid should be based on clinical condition and serum electrolytes at time of administration**
  - Balanced solutions (LR, PL) have lower risk of hyperchloremic metabolic acidosis and better outcomes in a variety of indications<sup>16-28</sup>
  - When rapid infusion needed, the first available isotonic fluid should be used
  - NS has hyper-physiological Na and Cl – may be useful for concerns of hyponatremia
  - Hypotonic solutions (0.45% saline, 0.2% saline, free water) should not be administered in a bolus dose
- **Patients with persistent severe hypovolemia, fluid-refractory or non-hypovolemic shock, and/or requirement of >2 bolus doses should be evaluated by PICU team (ACT)**

[Return to Bolus \(Hypovolemic\)  
Algorithm](#)

# Bolus IV Fluid Selection

- **Lactated Ringers (LR)**<sup>\$</sup>
  - isotonic, balanced
- **Normal Saline (NS)**<sup>\$</sup>
  - isotonic, unbalanced
- **PlasmaLyte (PL)**<sup>\$</sup>
  - isotonic, balanced; expensive, short supply

Human Plasma	Fluid Composition	Lactated Ringer's (LR)	0.9% Sodium Chloride (NS)	Plasma-Lyte (PL)
	Balanced or Unbalanced	Balanced	Unbalanced	Balanced
275-295	Osmolality (mOsm/kg)	273	308	295
7.35-7.45	pH	6-7.5	5	7.4
135-145	Sodium (mmol/L)	130	154	140
3.5-4.5	Potassium (mmol/L)	4	0	5
96-106	Chloride (mmol/L)	109	154	98
8.9-10.1	Calcium (mg/dL)	2.7	0	0
1.7-2.3	Magnesium (mg/dL)	0	0	3
0	Lactate (mmol/L)	28	0	0

[Return to Bolus \(Hypovolemic\) Algorithm](#)

[Further IVF Selection Guidance](#)

# Maintenance IV Fluid Selection

- **Lactated Ringers (LR)<sup>\$</sup>**
  - Isotonic, balanced (can bolus)
  - Near-physiologic
  - Dextrose, potassium may be added
- **Normal Saline (NS)<sup>\$</sup>**
  - Isotonic, unbalanced (can bolus)
  - Acidic and hypernatremic; risk of hyperchloremic metabolic acidosis
  - Dextrose, potassium may be added
- **Plasma-Lyte (PL)<sup>\$</sup>**
  - Isotonic, balanced (can bolus)
  - Expensive, limited availability – not first-line
  - Dextrose can NOT be added
- **0.45% Saline, 0.2% Saline**
  - Hypotonic, hyponatremic (cannot bolus)
  - Dextrose, potassium may be added
  - Not recommended first-line

Human Plasma	Fluid Composition	Lactated Ringer's (LR)	0.9% Sodium Chloride (NS)	0.45% Sodium Chloride (½ NS)	Plasma-Lyte (PL)
	Balanced or Unbalanced	Balanced	Unbalanced	Unbalanced	Balanced
275-295	Osmolality (mOsm/kg)	273	308	154	295
7.35-7.45	pH	6-7.5	5	5	7.4
135-145	Sodium (mmol/L)	130	154	77	140
3.5-4.5	Potassium (mmol/L)	4	0	0	5
96-106	Chloride (mmol/L)	109	154	77	98
8.9-10.1	Calcium (mg/dL)	2.7	0	0	0
1.7-2.3	Magnesium (mg/dL)	0	0	0	3
0	Lactate (mmol/L)	28	0	0	0

[Return to Maintenance \(Euvolemic\) Algorithm](#)

[Further IVF Selection Guidance](#)



# IV Fluids Selection Guidance

## Lactated Ringer's (LR)

- Safe for bolus use.
- LR has a similar composition to human plasma.
- Multiple studies have indicated lower incidence of sodium derangements, hyperchloremic metabolic acidosis (and associated mortality), and acute kidney injury (AKI) compared to saline solutions.<sup>16-28</sup>
- Dextrose and additional potassium may be added to LR.
- The presence of potassium must be considered in patients at risk for hyperkalemia. In patients with these risks (i.e. tumor lysis syndrome), fluids should be ordered with expert consultation.
- Physiological studies indicate 0.9% normal saline causes hyperkalemia more frequently than LR due to acidosis causing shifting of potassium from cells.<sup>14,29</sup>

## 0.9% Sodium Chloride (NS)

- Safe for bolus use.
- NS is an isotonic solution with a hyperphysiologic levels of sodium and chloride. The elevated sodium content can be useful with concerns for hyponatremia or brain injury.
- Dextrose and potassium may be added to NS.
- Use of NS is associated with AKI and can cause a hyperchloremic metabolic acidosis which is associated with significant adverse clinical outcomes.<sup>14,18,19,26-29</sup>
- Concerns for hypernatremia secondary to NS usage have been less well-founded in the literature.

## Plasma-Lyte (PL)

- Safe for bolus use.
- Plasma-Lyte has a similar composition to human plasma. Similar to LR, multiple studies have indicated lower incidence of sodium derangements, hyperchloremic metabolic acidosis (and associated mortality), and acute kidney injury (AKI) compared to saline solutions.<sup>16-28</sup>
- The presence of potassium should be considered in patients at risk for hyperkalemia, including tumor lysis syndrome.
- Plasma-Lyte cannot be made to contain dextrose. It is also expensive and available in significantly shorter supply.

## 0.45% Sodium Chloride (½ NS)

- Not safe for bolus use.
- ½ NS is a hypotonic solution that provides a decreased total sodium load compared to LR and NS. Dextrose and potassium may be added.
- In patients with normal physiological function, the kidneys excrete free water and prevent hyponatremia, however many hospitalized patients have risk factors for increased ADH secretion.<sup>6,8,30</sup> Hypotonic fluids and increased ADH secretion can put these patients at risk for hyponatremia. Significant hyponatremia is known to cause lethargy, seizures, coma, cerebral edema, and has an association with mortality.<sup>6,8,30</sup>
- ½ NS and other hypotonic fluids are not recommended as first-line maintenance fluids for the patients included in this guideline.<sup>10</sup>

[Return to Maintenance \(Euvolemic\)  
Algorithm](#)

[Return to Bolus \(Hypovolemic\)  
Algorithm](#)



# IV Fluid Additives

## Potassium

Use	Monitoring	Contraindications
<ul style="list-style-type: none"><li>• <u>NS</u>: consider 10-20 mEq/L of K (at 1x maintenance rate).</li><li>• <u>LR</u>: contains 4 mEq/L of K. Additional K may be added.</li><li>• <u>PL</u>: contains 5 mEq/L of K.</li></ul>	<ul style="list-style-type: none"><li>• Monitor/adjust K with labs (chem7, BMP, RFP)</li><li>• If adjusting fluid rate, consider adjusting K concentration</li></ul>	<ul style="list-style-type: none"><li>• Anuria, significant renal injury</li><li>• Rhabdomyolysis</li><li>• Tumor lysis syndrome</li><li>• Use of K-sparing diuretics</li><li>• Other pre-disposing conditions to hyperkalemia</li></ul>

## Dextrose

Dextrose 5% (D5)	Dextrose 10% (D10)
<ul style="list-style-type: none"><li>• Indicated in all patients &lt; 1 year old with absent enteral intake</li><li>• Consider in patients &lt; 10 years old with absent enteral intake or risk factors for hypoglycemia</li><li>• As otherwise clinically indicated</li></ul>	<ul style="list-style-type: none"><li>• Treatment for hypoglycemia</li></ul>

[Return to Maintenance \(Euvolemic\)  
Algorithm](#)

# Compatibility

- **Ceftriaxone and LR**<sup>15</sup>
  - Due to calcium content of LR (risk of ceftriaxone-calcium precipitation)
  - Ceftriaxone and LR may be used if line is adequately flushed before and after administration with saline
  - Ceftriaxone should not be used with LR in patients < 28 days even with separate lines
- **Chemotherapy, Malignancy, Tumor Lysis Syndrome:**
  - Intravenous fluids guided by oncologist and chemotherapy protocol in patients admitted to oncology
- **Transfusions and LR**<sup>13,31</sup>
  - Packed RBCs may be administered with LR in a separate line
- **Lactic Acid and LR**<sup>13</sup>
  - LR contains sodium lactate, not lactic acid, and this is metabolized by the liver
  - Sodium lactate does not share lactic acid's harmful effects
  - Lactate may theoretically accumulate in patients with liver failure; fluid resuscitation in patients with known hepatic dysfunction should be done with expert consultation

[Return to Maintenance \(Euvolemic\)  
Algorithm](#)

# IVF Rate Calculation

Holliday-Segar “4-2-1” rule. <sup>2</sup>	Example: 39kg child
<ul style="list-style-type: none"><li>• First 1-10 kg = 4 mL/kg/hr</li><li>• Next 11-20 kg = 2 mL/kg/hr</li><li>• Next &gt; 20 kg = 1 mL/kg/hr</li><li>• Add together for maintenance rate</li></ul>	<ul style="list-style-type: none"><li>• 10 kg x 4 mL/kg/hr = 40 mL/hr</li><li>• 10 kg x 2 mL/kg/hr = 20 mL/hr</li><li>• Remaining 19 kg x 1 mL/kg/hr = 19 mL/hr</li><li>• Maintenance rate = 79 mL/hr</li></ul>

- It is appropriate to have a maximum fluid rate of 100 mL/hr in most patients.

[Return to Maintenance \(Euvolemic\) Algorithm](#)

# Monitoring

- The major complications of maintenance fluid administration include volume overload, sodium derangements, hyperchloremic metabolic acidosis, potassium derangements, glucose derangements, and changes in renal function.
- Clinical volume status, weight, and intake/output should be monitored daily for all patients on mIVF.
- Serum electrolytes should be monitored in patients receiving IVFs, with strong recommendation to initiate monitoring within 48 hours of IVF initiation and then daily until IVFs have been discontinued
- If there is concern for development of hyperchloremic metabolic acidosis (chloride  $\geq 110$  mmol/L, bicarbonate  $\leq 18$  mmol/L)<sup>19</sup>, a venous blood gas may be obtained.

[Return to Maintenance \(Euvolemic\)  
Algorithm](#)

# Signs of Hypervolemia/Volume Overload

- Peripheral edema
- Hepatomegaly
- Pulmonary edema
- Hypertension
- Ascites
- Elevated jugular venous pressure

[Return to Maintenance \(Euvolemic\)  
Algorithm](#)

# Metrics

**Goal:**

Increase evidence-based IVF ordering to minimize electrolyte abnormalities and promote earlier transition to optimal nutrition routes.

**Process Measures:**

1. Utilization of standardized Epic tools to order IVFs.
2. Increase rate of lab monitoring for patients receiving maintenance IVFs.

**Quality Measures:**

1. Minimize number of patients receiving MIVF therapy greater than 5 days.
2. Increase percentage of patients receiving balanced and isotonic IVFs (Lactated Ringers and PlasmaLyte) for non-ICU patients greater than 28 days of age.
3. Minimize incidence of hyponatremia ( $\text{Na} < 135$ ) and hyperchloremic metabolic acidosis ( $\text{Cl} > 110$  and concurrent  $\text{CO}_2 < 18$ ) after initiation of maintenance IVFs for non-ICU patients greater than 28 days of age.

**Balancing Measures:**

1. Re-initiation of IV fluids within 48 hrs
2. Hospital LOS of patients on IV Fluids
3. Duration and cost of IV fluid therapy

[Return to Maintenance \(Euvolemic\)  
Algorithm](#)

[Further IVF Selection Guidance](#)

# References

1. TALBOT NB, CRAWFORD JD, BUTLER AM. Homeostatic limits to safe parenteral fluid therapy. *N Engl J Med*. Jun 1953;248(26):1100-8.

2. HOLLIDAY MA, SEGAR WE. The maintenance need for water in parenteral fluid therapy. *Pediatrics*. May 1957;19(5):823-32.

3. Foster BA, Tom D, Hill V. Hypotonic versus isotonic fluids in hospitalized children: a systematic review and meta-analysis. *J Pediatr*. Jul 2014;165(1):163-169.e2. doi:10.1016/j.jpeds.2014.01.040

4. McNab S, Ware RS, Neville KA, et al. Isotonic versus hypotonic solutions for maintenance intravenous fluid administration in children. *Cochrane Database Syst Rev*. Dec 2014;(12):CD009457. doi:10.1002/14651858.CD009457.pub2

5. Padua AP, Macaraya JR, Dans LF, Anacleto FE. Isotonic versus hypotonic saline solution for maintenance intravenous fluid therapy in children: a systematic review. *Pediatr Nephrol*. Jul 2015;30(7):1163-72. doi:10.1007/s00467-014-3033-y

6. Wang J, Xu E, Xiao Y. Isotonic versus hypotonic maintenance IV fluids in hospitalized children: a meta-analysis. *Pediatrics*. Jan 2014;133(1):105-13. doi:10.1542/peds.2013-2041

7. McNab S, Duke T, South M, et al. 140 mmol/L of sodium versus 77 mmol/L of sodium in maintenance intravenous fluid therapy for children in hospital (PIMS): a randomised controlled double-blind trial. *Lancet*. Mar 2015;385(9974):1190-7. doi:10.1016/S0140-6736(14)61459-8

8. Rey C, Los-Arcos M, Hernández A, Sánchez A, Díaz JJ, López-Herce J. Hypotonic versus isotonic maintenance fluids in critically ill children: a multicenter prospective randomized study. *Acta Paediatr*. Aug 2011;100(8):1138-43. doi:10.1111/j.1651-2227.2011.02209.x

9. Hoorn EJ. Intravenous fluids: balancing solutions. *J Nephrol*. Aug 2017;30(4):485-492. doi:10.1007/s40620-016-0363-9

10. Feld LG, Neuspiel DR, Foster BA, et al. Clinical Practice Guideline: Maintenance Intravenous Fluids in Children. *Pediatrics*. 12 2018;142(6)doi:10.1542/peds.2018-3083

11. Soranno D, Tchou M, Ahearn A, et al. Clinical Pathway: Intravenous Fluid Therapy. Children's Hospital Colorado 2019. p. 13.

12. Kwon S, Lin H, Oraziaka N, et al. Evidence Based Clinical Pathway: Acute Gastroenteritis/Dehydration. Nationwide Children's Hospital Clinical Pathways Program 2019. p. 9.

13. Singh S, Kerndt CC, Davis D. Ringer's Lactate. StatPearls - NCBI Bookshelf. *StatPearls Publishing*; 2021. <https://www.ncbi.nlm.nih.gov/books/NBK500033/?report=printable>

14. Li H, Sun SR, Yap JQ, Chen JH, Qian Q. 0.9% saline is neither normal nor physiological. *J Zhejiang Univ Sci B*. Mar 2016;17(3):181-7. doi:10.1631/jzus.B1500201

15. Lactated Ringer's Injection, USP, 2021

16. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. *Pediatr Crit Care Med*. 02 2020;21(2):e52-e106. doi:10.1097/PCC.0000000000002198

17. Emrath ET, Fortenberry JD, Travers C, McCracken CE, Hebbar KB. Resuscitation With Balanced Fluids Is Associated With Improved Survival in Pediatric Severe Sepsis. *Crit Care Med*. Jul 2017;45(7):1177-1183. doi:10.1097/CCM.0000000000002365

18. Stenson EK, Cvijanovich NZ, Allen GL, et al. Hyperchloremia is associated with acute kidney injury in pediatric patients with septic shock. *Intensive Care Med*. 11 2018;44(11):2004-2005. doi:10.1007/s00134-018-5368-5

19. Stenson EK, Cvijanovich NZ, Anas N, et al. Hyperchloremia Is Associated With Complicated Course and Mortality in Pediatric Patients With Septic Shock. *Pediatr Crit Care Med*. 02 2018;19(2):155-160. doi:10.1097/PCC.0000000000001401

20. Farrell PR, Farrell LM, Hornung L, Abu-El-Haija M. Use of Lactated Ringers Solution Compared With Normal Saline Is Associated With Shorter Length of Stay in Pediatric Acute Pancreatitis. *Pancreas*. 03 2020;49(3):375-380. doi:10.1097/MPA.0000000000001498

21. Bergmann KR, Abuzzahab MJ, Nowak J, et al. Resuscitation With Ringer's Lactate Compared With Normal Saline for Pediatric Diabetic Ketoacidosis. *Pediatr Emerg Care*. Jul 2018;doi:10.1097/PEC.0000000000001550

22. Lima MF, Neville IS, Cavalheiro S, Bourguignon DC, Pelosi P, Malbouisson LMS. Balanced Crystalloids Versus Saline for Perioperative Intravenous Fluid Administration in Children Undergoing Neurosurgery: A Randomized Clinical Trial. *J Neurosurg Anesthesiol*. Jan 2019;31(1):30-35. doi:10.1097/ANA.0000000000000515

23. Zunini GS, Rando KA, Cox RG. Fluid replacement in craniofacial pediatric surgery: normal saline or ringer's lactate? *J Craniofac Surg*. Jul 2011;22(4):1370-4. doi:10.1097/SCS.0b013e31821c94db

24. Hsia DS, Tarai SG, Alimi A, Coss-Bu JA, Haymond MW. Fluid management in pediatric patients with DKA and rates of suspected clinical cerebral edema. *Pediatr Diabetes*. Aug 2015;16(5):338-44. doi:10.1111/pedi.12268

25. Kartha GB, Rameshkumar R, Mahadevan S. Randomized Double-blind Trial of Ringer Lactate Versus Normal Saline in Pediatric Acute Severe Diarrheal Dehydration. *J Pediatr Gastroenterol Nutr*. 12 2017;65(6):621-626. doi:10.1097/MPG.0000000000001609

26. Self WH, Semler MW, Wanderer JP, et al. Balanced Crystalloids versus Saline in Noncritically Ill Adults. *N Engl J Med*. 03 2018;378(9):819-828. doi:10.1056/NEJMoa1711586

27. Semler MW, Wanderer JP, Ehrenfeld JM, et al. Balanced Crystalloids versus Saline in the Intensive Care Unit. The SALT Randomized Trial. *Am J Respir Crit Care Med*. 05 2017;195(10):1362-1372. doi:10.1164/rccm.201607-1345OC

28. Semler MW, Self WH, Rice TW. Balanced Crystalloids versus Saline in Critically Ill Adults. *N Engl J Med*. 05 2018;378(20):1951. doi:10.1056/NEJMc1804294

29. Santi M, Lava SA, Camozzi P, et al. The great fluid debate: saline or so-called "balanced" salt solutions? *Ital J Pediatr*. Jun 2015;41:47. doi:10.1186/s13052-015-0154-2

30. Moritz ML, Ayus JC. Hospital-acquired hyponatremia--why are hypotonic parenteral fluids still being used? *Nat Clin Pract Nephrol*. Jul 2007;3(7):374-82. doi:10.1038/ncpneph0526

31. Cull DL, Lally KP, Murphy KD. Compatibility of packed erythrocytes and Ringer's lactate solution. *Surg Gynecol Obstet*. Jul 1991;173(1):9-12.

32. Romero H, Rooholamini S. Maintenance IV Fluid Management. Seattle Children's Hospital: Clinical Practice Guidelines 2015. p. 24.

33. Rooholamini SN, Clifton H, Haaland W, McGrath C, Vora SB, Crowell CS, et al. Outcomes of a Clinical Pathway to Standardize Use of Maintenance Intravenous Fluids. *Hosp Pediatr*. 2017;7(12):703-9. TALBOT NB, CRAWFORD JD, BUTLER AM. Homeostatic limits to safe parenteral fluid therapy. *N Engl J Med*. Jun 1953;248(26):1100-8. doi:10.1056/NEJM195306252482605

34. Rooholamini SN, Jennings B, Zhou C, Kaiser SV, Garber MD, Tchou MJ, Ralston SL. Effect of a Quality Improvement Bundle to Standardize the Use of Intravenous Fluids for Hospitalized Pediatric Patients: A Stepped-Wedge, Cluster Randomized Clinical Trial. *JAMA Pediatr*. 2022 Jan 1;176(1):26-33. doi: 10.1001/jamapediatrics.2021.4267. PMID: 34779837; PMCID: PMC8593833.

[\*\*Return to Maintenance \(Euvolemic\) Algorithm\*\*](#)

[\*\*Return to Bolus \(Hypovolemic\) Algorithm\*\*](#)



# Team & Process

## Pathway Development Team

### Leader(s):

Hospital Pediatrics:

Allison Rossetti, MD

Resident, Internal Medicine-Pediatrics:

Matthew Schreier, MD

### Members:

Hospital Pediatrics:

Joshua Black, MD

Gerd McGwire, MD, PhD

Luke McKnight, MD

Critical Care:

Jennifer MacDonald, MD, PhD

Nephrology:

Tahagod Mohamed, MD

Clinical Pharmacy

Weslie Donia, PharmD

General Medicine H9A:

Stephen Humphrey, RN

## Clinical Pathways Program:

Medical Director – Hospital Pediatrics:

Gerd McGwire, MD, PhD

Medical Director – Clinical Informatics & Emergency Medicine:

Laura Rust, MD, MPH

Business & Development Manager:

Rekha Voruganti, MBOE, LSSBB

Program Coordinators:

Tara Dinh, BS

Clinical Pathway Approved

Medical Director – Associate Chief Quality Officer, Center for Clinical Excellence:

Ryan Bode, MD, MBOE

Origination Date: *September, 2022*

Next Revision Date: *September, 2025*

## Clinical Pathway Development

This clinical pathway was developed using the process described in the NCH Clinical Pathway Development Manual Version 6, 2022. Clinical Pathways at Nationwide Children's Hospital (NCH) are standards which provide general guidance to clinicians. Patient choice, clinician judgment, and other relevant factors in diagnosing and treating patients remain central to the selection of diagnostic tests and therapy. The ordering provider assumes all risks associated with care decisions. NCH assumes no responsibility for any adverse consequences, errors, or omissions that may arise from the use or reliance on these guidelines. NCH's clinical pathways are reviewed periodically for consistency with new evidence; however, new developments may not be represented, and NCH makes no guarantees, representations, or warranties with respect to the information provided in this clinical pathway.

Copyright © 2023. Nationwide Children's Hospital. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without the express written permission of Nationwide Children's Hospital.

**For more information about our pathways and program please contact:  
[ClinicalPathways@NationwideChildrens.org](mailto:ClinicalPathways@NationwideChildrens.org)**

**[Return to Maintenance \(Euvolemic\)  
Algorithm](#)**

**[Return to Bolus \(Hypovolemic\)  
Algorithm](#)**